Comorbidity in bullous pemphigoid: up-date and clinical implications

Abstract

Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients

“…Table II depicts the prevalence of comorbid conditions in the study and control groups ( 19 ). A statistically significant higher rate of Alzheimer’s disease and other dementias, essential hypertension, and kidney failure was observed in BP patients who received DPP-4i, compared with DM2 patients treated with gliptins but who did not develop BP.…”